Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Solutions--Er, Harvard Bioscience--Nabs Hybridization Patent

NEW YORK, Dec. 2 - A Harvard Bioscience subsidiary has won a patent for a hybridization technology that currently features in a pair of marketed devices.

 

The patent, announced last week, is the second one for this particular technology, developed by Harvard Bioscience's Genomic Solutions unit, Harvard said.

 

US Patent No. 6,432,696, entitled "Thermal and Fluidic Cycling Device for Nucleic Acid Hybridization," describes "a system that automates the processing of DNA and protein microarrays," according to Harvard Bioscience, which bought Genomic Solutions in October. The technology has already enjoyed wide market exposure: Genomic Solutions' GeneTAC Hybstation and GeneTAC Hyb4 "rely" on the technology described in both patents.

 

"Hybridization is a key step in any microarray experiment but one that can introduce unwanted variability," according to John D'Errico, Genomic Solutions' global marketing manager for genomics. The automation of the Hybstation and Hyb4 "eliminate a great deal of human error" from microarray experiments, he said. "We believe this reduces variability and gives researchers better data."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more